AbbVie Inc (ABBV)vsHaemonetics Corporation (HAE)
ABBV
AbbVie Inc
$205.03
-0.52%
HEALTHCARE · Cap: $365.43B
HAE
Haemonetics Corporation
$52.67
-5.30%
HEALTHCARE · Cap: $2.75B
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 4665% more annual revenue ($62.82B vs $1.32B). HAE leads profitability with a 13.3% profit margin vs 5.8%. ABBV appears more attractively valued with a PEG of 0.57. HAE earns a higher WallStSmart Score of 64/100 (C+).
ABBV
Buy63
out of 100
Grade: C+
HAE
Buy64
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-22.6%
Fair Value
$168.19
Current Price
$205.03
$36.84 premium
Margin of Safety
+44.1%
Fair Value
$102.84
Current Price
$52.67
$50.17 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 62 in profit
Strong operational efficiency at 31.6%
Conservative balance sheet, low leverage
Growing faster than its price suggests
Generating 4.9B in free cash flow
Growing faster than its price suggests
Attractively priced relative to earnings
Reasonable price relative to book value
Strong operational efficiency at 21.0%
Earnings expanding 28.4% YoY
Areas to Watch
5.8% margin — thin
Premium valuation, high expectations priced in
Earnings declined 45.8%
Distress zone — elevated risk
Distress zone — elevated risk
Elevated debt levels
Revenue declined 2.7%
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, Return on Equity, Operating Margin. Revenue growth of 12.4% demonstrates continued momentum. PEG of 0.57 suggests the stock is reasonably priced for its growth.
Bull Case : HAE
The strongest argument for HAE centers on PEG Ratio, P/E Ratio, Price/Book. PEG of 0.91 suggests the stock is reasonably priced for its growth.
Bear Case : ABBV
The primary concerns for ABBV are Profit Margin, P/E Ratio, EPS Growth. A P/E of 100.8x leaves little room for execution misses.
Bear Case : HAE
The primary concerns for HAE are Altman Z-Score, Debt/Equity, Revenue Growth.
Key Dynamics to Monitor
ABBV profiles as a value stock while HAE is a declining play — different risk/reward profiles.
ABBV carries more volatility with a beta of 0.36 — expect wider price swings.
ABBV is growing revenue faster at 12.4% — sustainability is the question.
ABBV generates stronger free cash flow (4.9B), providing more financial flexibility.
Bottom Line
HAE scores higher overall (64/100 vs 63/100). Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
Haemonetics Corporation
HEALTHCARE · MEDICAL DEVICES · USA
Haemonetics Corporation, a healthcare company, offers medical products and solutions. The company is headquartered in Boston, Massachusetts.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?